伊伐布雷定治疗慢性收缩性心力衰竭的临床效果评价  

Clinical effect of ivabradine in the treatment of chronic systolic heart failure

作　　者：刘燕飞[1] Liu Yanfei(The Fourth Hospital of Changsha City,Hunan Changsha 410006)

机构地区：[1]长沙市第四医院,湖南长沙410006

出　　处：《中国社区医师》2020年第14期34-34,36,共2页Chinese Community Doctors

摘　　要：目的:探讨伊伐布雷定治疗慢性收缩性心力衰竭的临床效果。方法:2016年7月-2018年11月收治慢性收缩性心力衰竭患者98例,随机分为两组,各49例。观察组给予基础治疗联合伊伐布雷定治疗;对照组给予基础治疗。比较两组6 min步行距离、左室射血分数及心电图恢复正常时间。结果:观察组6 min步行距离、左室射血分数、心电图恢复正常时间均优于对照组,差异有统计学意义(P<0.05)。结论:伊伐布雷定可有效增加慢性收缩性心力衰竭患者6 min步行距离,缩短其心电图恢复正常时间。Objective:To explore the clinical effect of ivabradine in the treatment of chronic systolic heart failure.Methods:From July 2016 to November 2018,98 patients with chronic systolic heart failure were selected and randomly divided into two groups with 49 cases in each group.The observation group was treated with basic treatment combined with ivabradine.The control group was treated with basic treatment.We compared the six minutes walking distance,left ventricular ejection fraction and the time of ECG recovery between the two groups.Results:In the observation group,the six minutes walking distance,left ventricular ejection fraction and the time of ECG recovery were better than the control group,the difference was statistically significant(P<0.05).Conclusion:Ivabradine can effectively increase the 6-minute walking distance of patients with chronic systolic heart failure,and shorten the time for their ECG to return to normal.

关 键 词：临床效果 慢性收缩性心力衰竭 伊伐布雷定 

分 类 号：R541.6[医药卫生—心血管疾病]